immunotherapy

Immunocore reports $106.7M Q1 KIMMTRAK sales, up 14% YoY, with landmark data showing doubled five-year survival in uveal melanoma patients.

ImmunityBio shares plunge 21% after FDA flags misleading cancer drug claims; $2B market cap erased. Securities lawsuit filed.

Molecular Partners published positive Phase 1 data for MP0317, a CD40 agonist, in Nature Cancer, demonstrating tumor microenvironment remodeling with favorable safety in advanced cancer patients.

Northwest Biotherapeutics appoints experienced biopharma executive Dr. Annalisa Jenkins as Strategic Adviser to advance its DCVax dendritic cell cancer vaccine platform.

IgA Nephropathy market projects 18.6% CAGR through 2036 from $1.5B base, driven by novel immunotherapies and recent FDA approvals reshaping kidney disease treatment.

Anixa Biosciences secures Mexican patent for breast cancer vaccine extending protection through 2040, supporting Phase 2 trial advancement.

ImmunityBio (IBRX) shares plunged 21% after FDA warning letter citing misleading efficacy claims about immunotherapy drug Anktiva. Class action lawsuit underway with May 26 deadline.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

AI technologies achieving 85-95% accuracy in biomarker identification are reshaping lung cancer drug discovery, with $3B in recent funding backing innovation by major pharma firms.

Compass Therapeutics to present Phase 2/3 data on tovecimig for biliary tract cancer on April 27, 2026, with 80% overall survival events achieved.

Inhibrx is fielding takeover interest from major pharma for cancer drug INBRX-106 in potential $9B spin-off; stock surges 39.86%.

Global vulvar cancer market expected to expand through 2035, driven by aging populations and HPV prevalence. Merck, Bristol Myers Squibb, and AstraZeneca lead innovation in immunotherapies despite reimbursement headwinds.

Kyverna's miv-cel shows statistically significant benefits across all endpoints in stiff person syndrome trial, with 81% achieving meaningful walking speed improvement.

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.

Northwest Biotherapeutics establishes dedicated UK leukapheresis clinic by June 2026, enabling scaled immunotherapy production and removing manufacturing bottlenecks.

Bispecific antibody market projected to reach $60 billion by 2031 from $16 billion in 2025, with 550+ clinical trials and 18 approved drugs driving sector transformation.

Beyond Cancer presented Phase 1 UNO trial data with six of ten patients alive 22-40 months post-treatment and secured U.S. patent for gas delivery technology.

Greenwich LifeSciences reports significant immune response gains in Phase III FLAMINGO-01 trial for GLSI-100 breast cancer recurrence prevention, showing 70-80% recurrence reduction.

Nanobiotix reports preclinical data showing nanoprimer technology improves DNA immunotherapy circulation while reducing hepatic toxicity in mouse models.

Immunocore's KIMMTRAK doubled five-year survival in metastatic uveal melanoma, achieving 16% vs. 8% control rate—longest T cell engager follow-up in solid tumors.